Publications

Authors:

Sotirchos, Elias S; Vasileiou, Eleni S; Salky, Rebecca; Huda, Saif; Mariotto, Sara; Chen, John J; Levy, Michael

Title:

Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin

Year:

2022

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

Elettronico

Referee:

Sì

Name of journal:

MULTIPLE SCLEROSIS AND RELATED DISORDERS

ISSN of journal:

2211-0348

N° Volume:

57

Number or Folder:

103462

Page numbers:

1-3

Keyword:

myelin oligodendrocyte glycoprotein antibody associated disease; MOGAD; relapse; subcutaneous Ig (SCIG); treatment

Short description of contents:

Myelin oligodendrocyte glycoprotein (MOG)-antibody associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system that often exhibits a relapsing course. Immune globulin (Ig) therapy has been proposed as maintenance therapy to prevent relapses in MOGAD, but existing reports are limited to the use of intravenous Ig (IVIG). Subcutaneous Ig (SCIG) may exhibit several advantages over IVIG, including self-administration and less systemic adverse effects. Herein, we report six patients with MOGAD who were treated with subcutaneous Ig (SCIG) with good tolerability and without any relapses during follow-up. This supports the rationale for prospective randomized studies of SCIG in MOGAD.

Web page:

https://doi.org/10.1016/j.msard.2021.103462

Product ID:

123758

Handle IRIS:

11562/1053962

Last Modified:

November 15, 2022

Bibliographic citation:

Sotirchos, Elias S; Vasileiou, Eleni S; Salky, Rebecca; Huda, Saif; Mariotto, Sara; Chen, John J; Levy, Michael, Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin «MULTIPLE SCLEROSIS AND RELATED DISORDERS» , vol. 57 , n. 103462 , 2022 , pp. 1-3

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo